Eli Lilly signs $2bn deal for AI drug development
Digest more
When patient safety, regulatory approval and real-world effectiveness are on the line, AI can't act autonomously.
5don MSN
Over the past decade, early-stage drug innovation has shifted toward China, researchers find
Early-stage drug development worldwide has nearly doubled over the past decade and shifted from a U.S.-dominated model to a ...
How over-the-top social media videos about psychedelics could undermine the field’s efforts to get its drugs approved.
The pharmaceutical industry is experiencing its own “DeepSeek moment,” according to science writer Hiya Jain. Just as the upstart AI breakthrough caught Silicon Valley off-guard, China is emerging as ...
OnKure Therapeutics Inc., a Boulder precision-oncology company that went public in 2024 via a merger with California-based Reneo Pharmaceuticals Inc., expects to raise about $150 million in a private ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results